Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Therapy-related MDS

Uma Borate • 1 Jun 2020
EHA 2020
Myelodysplastic Syndromes

Uma Borate, MD, of the Oregon Health & Science University, Portland, OR, discusses therapy-related myelodysplastic syndromes (MDS) and their under-representation in historic MDS trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Uma Borate

CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for hematologists
Eric Padron et al. • 25 Mar 2024
1:21
Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML
Uma Borate • 8 Dec 2023
1:34
Impact of pre-treatment features & choice of therapy on outcomes of older adults with AML
Uma Borate • 8 Dec 2023
1:10
Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study
Uma Borate • 8 Dec 2023

Related Videos

2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals